Global Hypersomnia Market Size Exceed To USD 5.42 Billion by 2035 | CAGR of 3.74% : Market Study Report

• As per Spherical Insights & Consulting, The Global Hypersomnia Market Size is expected to Grow from USD 3.62 Billion in 2024 to USD 5.42 Billion by 2035, at a CAGR of 3.74% during the forecast period 2025 to 2035, owing to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Hypersomnia Market Companies such as Jazz Pharmaceuticals, Harmony Biosciences, Axsome Therapeutics, Avadel Pharmaceuticals, Takeda Pharmaceutical Company, Centessa Pharmaceuticals, Bioprojet, Zevra Therapeutics, Teva Pharmaceuticals, Mylan N.V., Sun Pharma, Novartis AG, Pfizer Inc., Merck & Co., Eli Lilly and Company, and Others.

 

Hypersomnia Treatment Market: Understanding and Treatment Algorithm:

Hypersomnia is a sleep disorder characterized by excessive daytime sleepiness despite adequate or prolonged night-time sleep. Individuals may struggle to stay awake during the day, impacting daily activities and quality of life. Causes include neurological conditions, medication effects, or other sleep disorders, requiring medical evaluation and long-term management strategies.

 

Hypersomnia Diagnosis:

Diagnosis of hypersomnia involves a detailed medical history, sleep questionnaires, and objective sleep studies. Common tests include polysomnography to monitor sleep patterns overnight and the Multiple Sleep Latency Test (MSLT) to measure daytime sleepiness. Blood tests or brain imaging may be used to rule out underlying neurological or metabolic causes.

 

Hypersomnia Treatment:

Treatment of hypersomnia focuses on improving wakefulness and managing underlying causes. It may include stimulant medications like modafinil or solriamfetol, wake-promoting agents, and lifestyle adjustments such as regular sleep schedules. In some cases, cognitive behavioral therapy or treating coexisting conditions like sleep apnea or depression is also recommended for symptom control.

 

Hypersomnia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Hypersomnia, Gender-specific Diagnosed Incidence of Hypersomnia, Type-specific Diagnosed Incidence of Hypersomnia, Age-specific Diagnosed Incidence of Hypersomnia, Diagnosed Incident Population based on Primary Site of Hypersomnia, and Diagnosed Incident Population based on Histologic Classification of Hypersomnia Tumour in the global market covering North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of hypersomnia epidemiology in major markets worldwide.

 

Country Wise Hypersomnia Multiforme Epidemiology

• The epidemiology segment provides Hypersomnia prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia Pacific (including Japan), Latin America, the Middle East, and Africa.

 

Hypersomnia: Recent Development:

In June 2025, Avadel Pharmaceuticals received FDA orphan drug designation for LUMRYZ, its once-nightly extended release sodium oxybate medication, for treating idiopathic hypersomnia. The designation recognized its potential clinical superiority and provided incentives like market exclusivity. The REVITALYZ Phase 3 trial began enrollment to evaluate efficacy and safety in IH patients

 

Hypersomnia Marketed Drugs:

• Xywav: Jazz Pharmaceuticals

Xywav (calcium, magnesium, potassium, and sodium oxybates) is an FDA-approved central nervous system depressant used to treat idiopathic hypersomnia. It reduces excessive daytime sleepiness and improves nighttime sleep by modulating GABA activity. Its low-sodium formulation is preferred for patients requiring long-term therapy.

• Wakix: Harmony Biosciences

Wakix (pitolisant) is a histamine H receptor inverse agonist that promotes wakefulness by increasing histaminergic neurotransmission. FDA-approved for narcolepsy and being explored for idiopathic hypersomnia, it is a non-scheduled medication, offering a non-stimulant option with reduced abuse potential.

• Sunosi: Axsome Therapeutics

Sunosi (solriamfetol) is a dopaminem norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. It enhances alertness and wakefulness and is being explored for broader use in hypersomnia-related disorders.

 

Hypersomnia Market Outlook

• The hypersomnia market encompasses diagnosis, treatment, and management of conditions characterized by excessive daytime sleepiness, such as idiopathic hypersomnia and narcolepsy. It includes stimulant and non-stimulant medications, wake-promoting agents, emerging therapies, and supportive technologies designed to restore wakefulness and improve quality of life for affected patients.
• Rising prevalence of sleep disorders, increased awareness about hypersomnia, and advancements in neurostimulant therapies are key market drivers. The growing diagnosis rate due to improved screening methods and the demand for non-sedating, abuse-resistant treatment options continue to push innovation and market growth globally.
• Opportunities lie in the development of orexin-based therapies, personalized treatments, and non-invasive neuromodulation methods. Expanding research in pediatric and secondary hypersomnia, coupled with increased investment in rare disease pipelines and digital sleep monitoring tools, further enhances the potential for market expansion and diversification.
• Government bodies are supporting sleep disorder research through funding, rare disease designations, and accelerated drug approval pathways. Increased public health campaigns and inclusion of hypersomnia in national health registries are helping raise awareness and promote earlier diagnosis and treatment interventions globally.
• Lack of specific diagnostic biomarkers and limited approved therapies for idiopathic hypersomnia hinder early diagnosis and effective treatment.
• The market is expected to grow steadily due to increasing diagnosis rates and the development of orexin receptor-targeting therapies.

 

Hypersomnia Market Segmentation

By Classification:

• Idiopathic Hypersomnia
• Recurrent Hypersomnia
• Kleine-Levin Syndrome
• Secondary Hypersomnia

 

Idiopathic Hypersomnia holds the largest market share due to its chronic nature, high unmet treatment needs, and rising diagnosis rates. Patients often require long-term therapy, boosting demand for approved and emerging drugs. Growing awareness and clinical trial activity around idiopathic hypersomnia further drive its dominant position within the classification segment.

By Therapeutic Approach:

• Pharmacological Treatments
• Cognitive Behavioural Therapy
• Lifestyle Modifications
• Wakefulness-Promoting Agents

 

Pharmacological Treatments dominate the market due to their direct impact on reducing excessive daytime sleepiness. Widely used drugs like solriamfetol, pitolisant, and oxybates offer consistent symptom relief. Their accessibility, ongoing product development, and inclusion in treatment guidelines make them the preferred option, especially in moderate-to-severe hypersomnia cases globally.

 

Regional Segment Analysis of the Hypersomnia Market

 

North America holds the largest share in the hypersomnia market due to well-established healthcare infrastructure, advanced diagnostic systems, and high awareness about sleep disorders. The presence of major pharmaceutical companies and approved medications like Xywav and Wakix drives widespread treatment access. Supportive reimbursement policies and strong research activity also contribute to market dominance, making the region a hub for both clinical development and patient care in hypersomnia management.

 

Asia-Pacific is the fastest-growing region in the hypersomnia market, driven by improving healthcare systems, rising sleep disorder awareness, and increasing investments in sleep medicine. Countries like China, India, and Japan are experiencing greater diagnosis rates and expanding pharmaceutical access. Government-led health initiatives and a growing middle-class population are further enhancing demand for hypersomnia therapies, creating a favourable environment for market expansion and international collaborations in this therapeutic area.

 

Hypersomnia Market Key Companies

• Jazz Pharmaceuticals
• Harmony Biosciences
• Axsome Therapeutics
• Avadel Pharmaceuticals
• Takeda Pharmaceutical Company
• Centessa Pharmaceuticals
• Bioprojet
• Zevra Therapeutics
• Teva Pharmaceuticals
• Mylan N.V.
• Sun Pharma
• Novartis AG
• Pfizer Inc.
• Merck & Co.
• Eli Lilly and Company
• Others

 

Hypersomnia Therapeutics Market Report Scope

• The Hypersomnia therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Hypersomnia’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Hypersomnia therapies is provided, including an evaluation of new treatments expected to influence the current Hypersomnia treatment market landscape.
• The report includes a detailed review of the Hypersomnia therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based Hypersomnia Market Forecasting report offers valuable insights into trends shaping the global Hypersomnia market, helping to develop effective business strategies.

 

Hypersomnia Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Hypersomnia Therapeutic Approaches in Hypersomnia
• Review Of Drugs in Development for Hypersomnia
• Market, Growth, and Trends in Hypersomnia
• Market Opportunities in Hypersomnia Treatment
• Effects Of Future Therapies on Hypersomnia Treatment.

 

Hypersomnia Treatment Market Report Key Strengths

• 15 Years Hypersomnia Market Forecast
• Global Coverage
• Hypersomnia Epidemiology Segmentation
• Key Cross Competition

 

Hypersomnia Treatment Market Report Assessment

• Present Practices in the Hypersomnia Treatment Market
• Review of Investigational Hypersomnia Drugs
• Attractiveness of the Hypersomnia Drug Market
• Hypersomnia Market Drivers
• Hypersomnia Market Barriers
• SWOT
• Attribute Analysis

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the hypersomnia market based on the below-mentioned segments:

 

Global Hypersomnia Market, By Classification

• Idiopathic Hypersomnia
• Recurrent Hypersomnia
• Kleine-Levin Syndrome
• Secondary Hypersomnia

 

Global Hypersomnia Market, By Therapeutic Approach

• Pharmacological Treatments
• Cognitive Behavioural Therapy
• Lifestyle Modifications
• Wakefulness-Promoting Agents

 

Global Hypersomnia Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe